Introduction：When high-grade glioma recurs, the goal of reoperation is primarily cytoreduction. Intraoperatively, when tumor tissue is found to be exceptionally firm or densely adherent to eloquent cortex, leaving it behind is preferable to forcing the resection — subsequent treatment modalities continue to provide control.

When the first postoperative surveillance scan reveals a new enhancing lesion, the family grips the radiology report with sweating palms. Can surgery be done again? No question comes up more frequently in the neuro-oncology clinic.

The first thing a neurosurgeon looks at when the images go up is the morphology of the recurrence. If the enhancing lesion is confined to the margins of the original surgical cavity, has relatively well-defined borders, and has not spread diffusely along white matter fiber tracts, the opportunity for repeat resection is real. When the recurrence spreads along the corpus callosum, internal capsule, or corona radiata into a butterfly pattern on T2 FLAIR — or when multiple nodules are scattered across both hemispheres — the picture is one of diffuse recurrence: even if the surgeon enters, a clean resection is not achievable and the benefit is limited. A third pattern is distant recurrence: the original surgical site is clear, but a new enhancing lesion has appeared at a remote location, requiring an entirely fresh assessment of resectability at the new site — the same decision logic as for the initial operation. What the scan communicates goes beyond location. The sharpness of the boundary between the recurrent lesion and surrounding edema, its spatial relationship to eloquent cortex, and its proximity to branches of the anterior cerebral artery (ACA) or middle cerebral artery (MCA) all factor into the surgical decision. The intraoperative findings at repeat craniotomy also differ from those at the first operation: post-radiation brain parenchyma is more friable, hemostasis requires more frequent attention, and the interface between tumor and normal tissue is sometimes indistinguishable — unlike the first operation, where a relatively distinct gliotic margin often provides a plane for dissection.

The timing of recurrence also informs the decision. An enhancing lesion appearing within six months of completing initial radiotherapy may represent pseudoprogression — post-radiation inflammatory changes and increased vascular permeability can closely mimic the imaging appearance of true recurrence. Rushing to the operating room at this stage is an error. The standard approach is to assess rCBV on MR perfusion imaging, evaluate the Cho/NAA ratio on MR spectroscopy, and — at centers where it is available — add amino acid PET, synthesizing all available data to determine whether the lesion is genuine recurrence. Once true recurrence is confirmed, the interval since the initial operation becomes another reference point: the longer the interval, and the more favorable the molecular subtype (IDH-mutant, 1p/19q codeletion), the more clearly defined the benefit of reoperation tends to be.

The patient's systemic condition is an entirely separate accounting. When KPS drops below 60, when multiorgan dysfunction is present, or when nutritional status is severely compromised, the anesthetic itself becomes the first barrier — and wound healing capacity after surgery is also diminished. The scalp and bone flap in a previously irradiated field have inferior blood supply compared to unirradiated tissue; the rates of wound dehiscence and infection are higher than after the initial operation. The minimum physiological threshold for reoperation is a patient who is ambulatory, self-sufficient in daily activities, eating normally, and has broadly normal liver and renal function and an acceptable CBC. Families tend to panic when recurrence is confirmed and want to move toward the operating room immediately — but surgery cannot be rushed when the body is not ready, and there are no shortcuts in preoperative preparation.

Five things evaluated together: imaging, molecular subtype, timing, systemic condition, and neurological function. When high-grade glioma recurs, the primary goal of reoperation is cytoreduction. Intraoperatively, when tumor tissue is exceptionally firm or densely adherent to eloquent cortex, leaving it behind is preferable to forcing the resection — postoperative treatment continues to provide control. When low-grade glioma recurs in a localized pattern, gross total resection remains the goal. Some centers use intraoperative MRI (iMRI) to confirm the extent of resection in recurrent cases, but brain shift at repeat craniotomy is more pronounced than at initial surgery, reducing the accuracy of neuronavigation; intraoperative ultrasound is therefore used more frequently as a complementary tool.

Wound healing after repeat craniotomy is slower than after the first — this is determined by the biology of irradiated tissue and cannot be accelerated. Suture removal is sometimes pushed back by a week. Patients are instructed to avoid prolonged head-down positioning, suppress coughing, and keep the wound dry. These details may not always come up in preoperative counseling — but anyone who has been through it understands.

Reference: https://www.incsg.com/jiaozhiliu/8475.html